Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

NCT00974272 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of the medication exenatide on blood fat levels and inflammation after meals in adults with type 2 diabetes or prediabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 39 people

Who can join Ages 35–70 · all sexes

Timeline Started 2006-08 · est. completion 2008-11

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT00974272 ↗

Description as written by the study sponsor.

The primary goal of this study is to determine the acute effects of exenatide on postprandial hypertriglyceridemia. Secondary goals are to determine whether there are additional improvements in postprandial lipids and lipoproteins and whether (by the reduction of hyperglycemia alone or in combination with declines in hyperlipidemia) exenatide reduces the pro-inflammatory potential of the postprandial period.

Treatments tested

Exenatide also known as Byetta Drug

Single subcutaneous injection (10 μg)
Normal Saline Other

Single subcutaneous injection

Main thing measured	Triglyceride concentration in serum
Sponsor	Carl T. Hayden VA Medical Center
Conditions studied	Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00974272 ↗